Incyte Corporation (INCY)
Automate Your Wheel Strategy on INCY
With Tiblio's Option Bot, you can configure your own wheel strategy including INCY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol INCY
- Rev/Share 22.7824
- Book/Share 18.9331
- PB 3.4881
- Debt/Equity 0.0118
- CurrentRatio 2.0389
- ROIC 0.0029
- MktCap 12783362800.0
- FreeCF/Share 1.4909
- PFCF 44.2622
- PE 601.4453
- Debt/Assets 0.0075
- DivYield 0
- ROE 0.0064
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 4
- P/B Score 2
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | INCY | Guggenheim | Buy | Neutral | -- | -- | March 18, 2025 |
| Downgrade | INCY | William Blair | Outperform | Market Perform | -- | -- | March 18, 2025 |
| Initiation | INCY | UBS | -- | Neutral | -- | $77 | Dec. 17, 2024 |
| Initiation | INCY | Wolfe Research | -- | Outperform | -- | $84 | Oct. 1, 2024 |
| Downgrade | INCY | Truist | Buy | Hold | $83 | $74 | Sept. 18, 2024 |
News
Why Is Incyte (INCY) Up 3.6% Since Last Earnings Report?
Published: May 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Incyte (INCY) reported earnings 30 days ago. What's next for the stock?
Read More
Incyte Gets FDA Approval for Zynyz in New Cancer Indication
Published: May 16, 2025 by: Zacks Investment Research
Sentiment: Positive
The FDA approves INCY's Zynyz both as monotherapy and in combination with chemotherapy for treating advanced anal cancer.
Read More
Incyte Announces FDA Approval of Zynyz® (retifanlimab-dlwr) Making it the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States
Published: May 15, 2025 by: Business Wire
Sentiment: Neutral
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--FDA Approves Zynyz (retifanlimab-dlwr) the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States.
Read More
INCY Q1 Earnings & Revenues Beat Estimates on Higher Product Sales
Published: April 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Incyte reports better-than-expected first-quarter 2025 results, beating both earnings and revenue estimates, driven by strong Jakafi and Opzelura sales.
Read More
Here's What Key Metrics Tell Us About Incyte (INCY) Q1 Earnings
Published: April 29, 2025 by: Zacks Investment Research
Sentiment: Positive
The headline numbers for Incyte (INCY) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Read More
Incyte (INCY) Q1 Earnings and Revenues Top Estimates
Published: April 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Incyte (INCY) came out with quarterly earnings of $1.16 per share, beating the Zacks Consensus Estimate of $1.01 per share. This compares to earnings of $0.64 per share a year ago.
Read More
Why Incyte Stock Was Tanking This Week
Published: March 21, 2025 by: The Motley Fool
Sentiment: Neutral
A less-than-encouraging clinical trial for an investigative medicine was the news driving down Incyte (INCY 2.23%) stock over the past few days. The gloom this produced was pushing the biotech's share price down by nearly 11% week to date as of Friday before market open.
Read More
Incyte Is Today's Worst S&P 500 Stock. Here's Why.
Published: March 17, 2025 by: Barrons
Sentiment: Negative
The biopharmaceutical company announces positive results from two skin disease treatment studies. But Wall Street doesn't think it was enough.
Read More
Incyte Stock Eyes Worst Day Since 2018 After Trial Results
Published: March 17, 2025 by: Schaeffers Research
Sentiment: Negative
Incyte Corp (NASDAQ:INCY) stock is down 11.4% to trade at $60.16 at last glance, after the pharmaceutical company's phase three trial data for its skin disease treatment showed it was only effective for half of participants.
Read More
Incyte's New Treatment for Chronic Skin Disease Shows Promising Results In Latest Clinical Trials, Stock Falls
Published: March 17, 2025 by: Benzinga
Sentiment: Positive
On Monday, Incyte Corporation INCY released topline results from its pivotal Phase 3 STOP-HS clinical trial program of povorcitinib, an oral small-molecule JAK1 inhibitor, in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS).
Read More
INCY Opzelura Shows Superior Efficacy in 2 Prurigo Nodularis Studies
Published: March 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Incyte reports positive data from two phase III studies evaluating Opzelura for prurigo nodularis in adults.
Read More
LLY/INCY Olumiant Shows Superior Efficacy in Pediatric Alopecia Study
Published: March 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Eli Lilly and INCY announce positive efficacy data from the late-stage alopecia study of baricitinib in adolescent patients.
Read More
Incyte to Unveil New Data from its Dermatology Portfolio at 2025 American Academy of Dermatology (AAD) Annual Meeting
Published: February 28, 2025 by: Business Wire
Sentiment: Neutral
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #AAD2025--Incyte to Unveil New Data from its Dermatology Portfolio at 2025 American Academy of Dermatology (AAD) Annual Meeting.
Read More
Incyte and Genesis Therapeutics Announce Strategic AI-focused Research Collaboration
Published: February 20, 2025 by: Business Wire
Sentiment: Neutral
WILMINGTON, Del. & BURLINGAME, Calif.--(BUSINESS WIRE)--Incyte and Genesis Therapeutics announce strategic AI-focused research collaboration.
Read More
INCY's Q4 Earnings Miss Mark, Revenues Beat on Higher Product Sales
Published: February 10, 2025 by: Zacks Investment Research
Sentiment: Negative
Incyte reports mixed fourth-quarter 2024 results as earnings miss estimates while revenues beat the same. Jakafi and Opzelura drive year-over-year sales.
Read More
Incyte Corporation (INCY) Q4 2024 Earnings Call Transcript
Published: February 10, 2025 by: Seeking Alpha
Sentiment: Neutral
Incyte Corporation (NASDAQ:INCY ) Q4 2025 Earnings Conference Call February 10, 2025 8:00 AM ET Company Participants Ben Strain - Associate Vice President, Investor Relations Herve Hoppenot - Chief Executive Officer Pablo Cagnoni - President, Head of Research & Development Christiana Stamoulis - Chief Financial Officer Matteo Trotta - Executive Vice President, General Manager, U.S. Dermatology Conference Call Participants Tazeen Ahmad - Bank of America David Lebowitz - Citibank Jessica Fye - JPMorgan Salveen Richter - Goldman Sachs James Shin - Deutsche Bank Vikram Purohit - Morgan Stanley Marc Frahm - TD Cowen Kelly Shi - Jefferies Brian Abrams - …
Read More
Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance and Highlights 2025 R&D Milestones
Published: February 10, 2025 by: Business Wire
Sentiment: Neutral
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance and Highlights 2025 R&D Milestones.
Read More
About Incyte Corporation (INCY)
- IPO Date 1993-11-04
- Website https://www.incyte.com
- Industry Biotechnology
- CEO Mr. Herve Hoppenot
- Employees 2617